Triethylamine → (R)-2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2(1H)-yl)-4-(trifluoromethyl)pyrimidine-5-carboxamide

HRID 1521528Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 1521528
[OH:1][CH2:2][C:3]1[C:4]([S:32]([CH3:35])(=[O:34])=[O:33])=[CH:5][C:6]2[N:10]3[CH2:11][CH2:12][N:13]([C:18]4[N:23]=[C:22]([C:24]([F:27])([F:26])[F:25])[C:21]([C:28]([OH:30])=O)=[CH:20][N:19]=4)[C@H:14]([CH:15]([CH3:17])[CH3:16])[C:9]3=[N:8][C:7]=2[CH:31]=1.C[N:37](C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.CC[N:62](CC)CC.[NH4+].[Cl-]>CN(C=O)C.O>[OH:1][CH2:2][C:3]1[C:4]([S:32]([CH3:35])(=[O:33])=[O:34])=[CH:5][C:6]2[N:10]3[CH2:11][CH2:12][N:13]([C:18]4[N:23]=[C:22]([C:24]([F:25])([F:27])[F:26])[C:21]([C:28]([NH2:37])=[O:30])=[CH:20][N:19]=4)[C@H:14]([CH:15]([CH3:16])[CH3:17])[C:9]3=[N:8][C:7]=2[CH:31]=1.[OH:1][CH2:2][C:3]1[C:4]([S:32]([CH3:35])(=[O:33])=[O:34])=[CH:5][C:6]2[N:10]3[CH2:11][CH2:12][N:13]([C:18]4[N:23]=[C:22]([C:24]([F:25])([F:27])[F:26])[C:21]([C:28]([NH2:62])=[O:30])=[CH:20][N:19]=4)[C@@H:14]([CH:15]([CH3:16])[CH3:17])[C:9]3=[N:8][C:7]=2[CH:31]=1

Komponenten

8

Edukt 4

HCID 8471TriethylamineHCID 25517Ammonium ChlorideHCID 9886157Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 71736481(R)-2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2(1H)-yl)-4-(trifluoromethyl)pyrimidine-5-carboxylic acid

Produkt 2

HCID 71736631(R)-2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2(1H)-yl)-4-(trifluoromethyl)pyrimidine-5-carboxamideAusbeute 56,7 %HCID 71736632(S)-2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2(1H)-yl)-4-(trifluoromethyl)pyrimidine-5-carboxamideAusbeute 10,8 %

Reagenzien, Katalysatoren, Lösungsmittel 2

HCID 962WaterLösungsmittelHCID 6228DimethylformamideLösungsmittel

Versuchsvorschrift

To a solution of (R)-2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2(1H)-yl)-4-(trifluoromethyl)pyrimidine-5-carboxylic acid (100 mg, 0.19 mmol, partially racemized) in DMF (2 mL) was added HATU (97 mg, 0.25 mmol) and Et3N (52 mg, 0.51 mmol). The mixture was stirred at rt for 1 h. NH4Cl (19 mg, 0.34 mmol) was added in one portion. The mixture was stirred at rt for 16 h. Water (10 mL) was added and the aqueous layer was extracted with EtOAc (4×10 mL). The combined organic layers were washed with water (3×10 mL) and brine, dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The residue was purified by preparative TLC and SFC separation to afford (R)-2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2(1H)-yl)-4-(trifluoromethyl)pyrimidine-5-carboxamide (55.2 mg, 56.7% yield, isomer 1) as a white solid and (S)-2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2(1H)-yl)-4-(trifluoromethyl)pyrimidine-5-carboxamide (10.5 mg, 10.8% yield, isomer 2) as white solid.

Aufarbeitung

  1. stirringThe mixture was stirred at rt for 16 h
  2. extractionthe aqueous layer was extracted with EtOAc (4×10 mL)
  3. washThe combined organic layers were washed with water (3×10 mL) and brine
  4. dry with materialdried over anhydrous Na2SO4
  5. filtrationfiltered
  6. concentrationconcentrated under vacuum
  7. customThe residue was purified by preparative TLC and SFC separation

Quellen und Nachweise

ORD-Eintrag
ord-e53f8ee020ff4da198ca6d624c1f4081
Quelldatensatz
uspto-grants-2015_07
Patentnummer
US09073931B2

Notizen zur Reaktion

Wird geladen…